vs
安进（AMGN）与SELECT MEDICAL HOLDINGS CORP（SEM）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是SELECT MEDICAL HOLDINGS CORP的7.1倍（$9.9B vs $1.4B）。安进净利率更高（13.5% vs 1.4%，领先12.1%）。安进同比增速更快（8.6% vs 6.4%）。安进自由现金流更多（$961.0M vs $5.2M）。过去两年安进的营收复合增速更高（15.1% vs 2.8%）
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
Select Medical是总部位于美国宾夕法尼亚州的医疗健康企业，业务涵盖长期急症护理、住院康复医院运营，同时开设有职业健康与物理治疗诊所，母公司Select Medical Holdings在纽约证券交易所挂牌上市。
AMGN vs SEM — 直观对比
营收规模更大
AMGN
是对方的7.1倍
$1.4B
营收增速更快
AMGN
高出2.2%
6.4%
净利率更高
AMGN
高出12.1%
1.4%
自由现金流更多
AMGN
多$955.8M
$5.2M
两年增速更快
AMGN
近两年复合增速
2.8%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $9.9B | $1.4B |
| 净利润 | $1.3B | $20.2M |
| 毛利率 | 69.8% | — |
| 营业利润率 | 27.6% | 4.6% |
| 净利率 | 13.5% | 1.4% |
| 营收同比 | 8.6% | 6.4% |
| 净利润同比 | 112.6% | 225.7% |
| 每股收益（稀释后） | $2.45 | $0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMGNSEM
| Q4 25 | $9.9B | $1.4B | ||
| Q3 25 | $9.6B | $1.4B | ||
| Q2 25 | $9.2B | $1.3B | ||
| Q1 25 | $8.1B | $1.4B | ||
| Q4 24 | $9.1B | $1.3B | ||
| Q3 24 | $8.5B | $1.3B | ||
| Q2 24 | $8.4B | $1.3B | ||
| Q1 24 | $7.4B | $1.3B |
净利润AMGNSEM
| Q4 25 | $1.3B | $20.2M | ||
| Q3 25 | $3.2B | $28.8M | ||
| Q2 25 | $1.4B | $40.6M | ||
| Q1 25 | $1.7B | $56.7M | ||
| Q4 24 | $627.0M | $-16.1M | ||
| Q3 24 | $2.8B | $55.6M | ||
| Q2 24 | $746.0M | $77.6M | ||
| Q1 24 | $-113.0M | $96.9M |
毛利率AMGNSEM
| Q4 25 | 69.8% | — | ||
| Q3 25 | 67.8% | — | ||
| Q2 25 | 67.2% | — | ||
| Q1 25 | 63.6% | — | ||
| Q4 24 | 65.7% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 61.4% | — | ||
| Q1 24 | 57.0% | — |
营业利润率AMGNSEM
| Q4 25 | 27.6% | 4.6% | ||
| Q3 25 | 26.4% | 5.4% | ||
| Q2 25 | 28.9% | 6.5% | ||
| Q1 25 | 14.5% | 8.3% | ||
| Q4 24 | 25.4% | 1.6% | ||
| Q3 24 | 24.1% | 4.3% | ||
| Q2 24 | 22.8% | 5.8% | ||
| Q1 24 | 13.3% | 9.0% |
净利率AMGNSEM
| Q4 25 | 13.5% | 1.4% | ||
| Q3 25 | 33.7% | 2.1% | ||
| Q2 25 | 15.6% | 3.0% | ||
| Q1 25 | 21.2% | 4.2% | ||
| Q4 24 | 6.9% | -1.2% | ||
| Q3 24 | 33.3% | 4.4% | ||
| Q2 24 | 8.9% | 6.1% | ||
| Q1 24 | -1.5% | 7.3% |
每股收益（稀释后）AMGNSEM
| Q4 25 | $2.45 | $0.17 | ||
| Q3 25 | $5.93 | $0.23 | ||
| Q2 25 | $2.65 | $0.32 | ||
| Q1 25 | $3.20 | $0.44 | ||
| Q4 24 | $1.17 | $-0.12 | ||
| Q3 24 | $5.22 | $0.43 | ||
| Q2 24 | $1.38 | $0.60 | ||
| Q1 24 | $-0.21 | $0.75 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.1B | $26.5M |
| 总债务越低越好 | $54.6B | $1.8B |
| 股东权益账面价值 | $8.7B | $1.7B |
| 总资产 | $90.6B | $5.9B |
| 负债/权益比越低杠杆越低 | 6.31× | 1.06× |
8季度趋势，按日历期对齐
现金及短期投资AMGNSEM
| Q4 25 | $9.1B | $26.5M | ||
| Q3 25 | $9.4B | $60.1M | ||
| Q2 25 | $8.0B | $52.3M | ||
| Q1 25 | $8.8B | $53.2M | ||
| Q4 24 | $12.0B | $59.7M | ||
| Q3 24 | $9.0B | $191.5M | ||
| Q2 24 | $9.3B | $111.2M | ||
| Q1 24 | $9.7B | $92.6M |
总债务AMGNSEM
| Q4 25 | $54.6B | $1.8B | ||
| Q3 25 | $54.6B | $1.7B | ||
| Q2 25 | $56.2B | $1.8B | ||
| Q1 25 | $57.4B | $1.8B | ||
| Q4 24 | $60.1B | $1.7B | ||
| Q3 24 | $60.4B | $3.1B | ||
| Q2 24 | $62.6B | $3.6B | ||
| Q1 24 | $64.0B | $3.8B |
股东权益AMGNSEM
| Q4 25 | $8.7B | $1.7B | ||
| Q3 25 | $9.6B | $1.7B | ||
| Q2 25 | $7.4B | $1.7B | ||
| Q1 25 | $6.2B | $1.7B | ||
| Q4 24 | $5.9B | $1.7B | ||
| Q3 24 | $7.5B | $1.9B | ||
| Q2 24 | $5.9B | $1.4B | ||
| Q1 24 | $5.0B | $1.4B |
总资产AMGNSEM
| Q4 25 | $90.6B | $5.9B | ||
| Q3 25 | $90.1B | $5.7B | ||
| Q2 25 | $87.9B | $5.7B | ||
| Q1 25 | $89.4B | $5.7B | ||
| Q4 24 | $91.8B | $5.6B | ||
| Q3 24 | $90.9B | $8.0B | ||
| Q2 24 | $90.9B | $7.9B | ||
| Q1 24 | $93.0B | $7.9B |
负债/权益比AMGNSEM
| Q4 25 | 6.31× | 1.06× | ||
| Q3 25 | 5.67× | 1.03× | ||
| Q2 25 | 7.57× | 1.10× | ||
| Q1 25 | 9.24× | 1.03× | ||
| Q4 24 | 10.23× | 1.01× | ||
| Q3 24 | 8.02× | 1.62× | ||
| Q2 24 | 10.57× | 2.54× | ||
| Q1 24 | 12.75× | 2.75× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.6B | $64.3M |
| 自由现金流经营现金流 - 资本支出 | $961.0M | $5.2M |
| 自由现金流率自由现金流/营收 | 9.7% | 0.4% |
| 资本支出强度资本支出/营收 | 6.5% | 4.2% |
| 现金转化率经营现金流/净利润 | 1.20× | 3.19× |
| 过去12个月自由现金流最近4个季度 | $8.1B | $117.2M |
8季度趋势，按日历期对齐
经营现金流AMGNSEM
| Q4 25 | $1.6B | $64.3M | ||
| Q3 25 | $4.7B | $175.3M | ||
| Q2 25 | $2.3B | $110.3M | ||
| Q1 25 | $1.4B | $-3.5M | ||
| Q4 24 | $4.8B | $125.4M | ||
| Q3 24 | $3.6B | $181.0M | ||
| Q2 24 | $2.5B | $278.2M | ||
| Q1 24 | $689.0M | $-66.7M |
自由现金流AMGNSEM
| Q4 25 | $961.0M | $5.2M | ||
| Q3 25 | $4.2B | $122.2M | ||
| Q2 25 | $1.9B | $45.6M | ||
| Q1 25 | $980.0M | $-55.8M | ||
| Q4 24 | $4.4B | $62.0M | ||
| Q3 24 | $3.3B | $130.3M | ||
| Q2 24 | $2.2B | $222.6M | ||
| Q1 24 | $459.0M | $-119.2M |
自由现金流率AMGNSEM
| Q4 25 | 9.7% | 0.4% | ||
| Q3 25 | 44.4% | 9.0% | ||
| Q2 25 | 20.8% | 3.4% | ||
| Q1 25 | 12.0% | -4.1% | ||
| Q4 24 | 48.4% | 4.7% | ||
| Q3 24 | 39.0% | 10.2% | ||
| Q2 24 | 26.5% | 17.4% | ||
| Q1 24 | 6.2% | -9.0% |
资本支出强度AMGNSEM
| Q4 25 | 6.5% | 4.2% | ||
| Q3 25 | 4.6% | 3.9% | ||
| Q2 25 | 4.0% | 4.8% | ||
| Q1 25 | 5.0% | 3.9% | ||
| Q4 24 | 4.1% | 4.8% | ||
| Q3 24 | 3.0% | 4.0% | ||
| Q2 24 | 2.8% | 4.3% | ||
| Q1 24 | 3.1% | 4.0% |
现金转化率AMGNSEM
| Q4 25 | 1.20× | 3.19× | ||
| Q3 25 | 1.46× | 6.09× | ||
| Q2 25 | 1.59× | 2.72× | ||
| Q1 25 | 0.80× | -0.06× | ||
| Q4 24 | 7.61× | — | ||
| Q3 24 | 1.26× | 3.25× | ||
| Q2 24 | 3.30× | 3.59× | ||
| Q1 24 | — | -0.69× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
SEM
| Critical Illness Recovery Hospitals | $629.7M | 45% |
| Health Care Patient Service Non Medicare | $428.6M | 31% |
| Rehabilitation Hospitals | $339.2M | 24% |
